Synergypharma Formulations (India) Private Limited
About Synergypharma Formulations (India) Private Limited
Data last updated:
Synergypharma Formulations (India) Private Limited was a private limited company based in Thane, Maharashtra, India. The company has been struck off by the Registrar of Companies, typically due to non-filing of annual returns or failure to commence business. It is no longer operational and cannot enter into any legal contracts or agreements. It operated in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 14 June 2016.
The company was registered with the Registrar of Companies (ROC), Mumbai, under CIN U51909MH2016PTC282357. Its GSTIN is 27AAXCS2321N1ZQ (Maharashtra).
The company had an authorised share capital of ₹14 Lakh and a paid-up capital of ₹14 Lakh. It was led by directors Rajan Nair and Shalini Nair.
Its last annual general meeting (AGM) was held on 23 August 2023, and its latest financial statements are for the year ended 31 March 2023. The registered office was at F/304 Glory Apartment Satelite Park Next G.C. Club Mira Road East, Thane, Maharashtra, India – 401104.
As per the financials filed for FY 2023, the company reported a revenue of ₹36.11 Cr, reflecting significant growth compared to the previous year. For the same year it recorded a net profit of ₹36.08 Cr (net margin 99.9%) and EBITDA of ₹36.08 Cr (EBITDA margin 99.9%). Revenue has grown at a compounded annual rate (CAGR) of 89% over three years.
The company had about 88 employees on its provident fund (EPFO) records before it was struck off.
Company details
Contact details
Synergypharma Formulations (India) Private Limited's registered office is in Thane, Maharashtra. Its e-mail address is in the company report.
- Email
- Registered AddressF/304 Glory Apartment Satelite Park Next G.C. Club Mira Road East, Thane, Maharashtra, India – 401104
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Synergypharma Formulations (India) Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Financials of Synergypharma Formulations (India) Private Limited
FY 2023 filings availableSynergypharma Formulations (India) Private Limited reported revenue of ₹36.11 Cr (up 13135% YoY) for FY 2023.
Compounded Annual Growth Rate (CAGR)
Revenue has grown at a compounded annual rate (CAGR) of 89% over three years. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 | FY 2018-19 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹36.08 Cr | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹36.08 Cr | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 | FY 2018-19 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 99.9% | ||||
| Net Profit Margin | 99.9% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Synergypharma Formulations (India) Private Limited, buy the company report.
Board of directors of Synergypharma Formulations (India) Private Limited
Synergypharma Formulations (India) has 2 current directors and 3 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Rajan Nair | Director | 14 Jun 2016 | 10 Years 4 Months | As last reported |
| Shalini Nair | Director | 18 Feb 2020 | 6 Years 8 Months | As last reported |
Peer comparison
Synergypharma Formulations (India) Private Limited is compared with the 5 companies closest to it by revenue in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Vivimed Labs (Alathur) Private Limited | ₹36.32 Cr (FY 2016) | 29.0% | Mumbai, Maharashtra, India | |||
| Neptune Lifesciences Pvt Ltd | ₹36.25 Cr (FY 2024) | 15.0% | Solan H P, Himachal Pradesh, India | |||
| Synergypharma Formulations (India) Private Limitedthis company | ₹36.11 Cr (FY 2023) | ₹36.08 Cr | 99.9% | 13135.0% | 88 | Thane, Maharashtra, India |
| Suncare Formulations Private Limited | ₹36.05 Cr (FY 2025) | -2.0% | Dehradun, Uttarakhand, India | |||
| Prim Drugs & Pharmaceuticals (India) Private Limited | ₹35.97 Cr (FY 2024) | 62.0% | Sriperumbudur, Tamil Nadu, India | |||
| Challa Chlorides Pvt Ltd | ₹35.87 Cr (FY 2024) | 58.0% | Panjagutta, Hyderabad, Telangana, India |
To see the full peer comparison of Synergypharma Formulations (India) Private Limited, buy the company report.
Auditor
Synergypharma Formulations (India) Private Limited is audited by VIVEK V JOSHI & ASSOCIATES for the financial year 2018.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| VIVEK V JOSHI & ASSOCIATES | FY 2018 | 121829W |
Shareholding
The shareholding of Synergypharma Formulations (India) Private Limited is on record for 2 financial years, the latest being FY 2018, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2018 | FY 2017 |
|---|---|---|
| Promoters | ||
| Domestic institutional investors (DII) | ||
| Foreign institutional investors (FII) | ||
| Public | ||
| Others |
To see the full shareholding pattern of Synergypharma Formulations (India) Private Limited, buy the company report.
Legal cases
No court or tribunal cases involving Synergypharma Formulations (India) Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Synergypharma Formulations (India) Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
Employees & EPFO
Synergypharma Formulations (India) Private Limited has a workforce of 88 employees on its EPFO records as of Apr 08, 2024, across 1 active EPFO establishment.
GST
Synergypharma Formulations (India) has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 27AAXCS2321N1ZQ | Maharashtra | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Synergypharma Formulations (India) Private Limited, buy the company report.
Recent activity
Synergypharma Formulations (India) Private Limited has 5 board changes on record since 2016: 2 appointments and 3 cessations. The latest: Subramanian Ramaswamy Vaidya ceased to be Director on 21 Oct 2023.
Frequently asked questions
Synergypharma Formulations (India) has a status of "Struck Off" as per MCA records. This means the company has been officially removed from the Register of Companies, typically due to non-filing of annual returns or failure to commence business within one year of incorporation. A struck-off company cannot enter into any legal contracts or agreements, and any dealings with such an entity carry significant legal and financial risk.
Synergypharma Formulations (India) was a private limited company based in Thane, Maharashtra, India. The company worked in drug formulation and development, within the pharma industry. It was incorporated on 14 June 2016 and is registered under CIN U51909MH2016PTC282357. The company has been struck off by the Registrar of Companies and is no longer operational.
Synergypharma Formulations (India) had 2 directors:
- Rajan Nair - Director
- Shalini Nair - Director
The CIN (Corporate Identification Number) of Synergypharma Formulations (India) is U51909MH2016PTC282357. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
The registered office of Synergypharma Formulations (India) is at F304 Glory Apartment Satelite Park Next G.C. Club Mira Road East, Thane, Maharashtra, India – 401104.
Synergypharma Formulations (India) was incorporated on 14 June 2016. It is registered with the Registrar of Companies, Mumbai.
The latest financial statements of Synergypharma Formulations (India) on record with the MCA are for the year ended 31 March 2023. Its last annual general meeting was held on 23 August 2023. Year-wise statements from FY 2017 are in the company report.
The GSTIN of Synergypharma Formulations (India) is 27AAXCS2321N1ZQ, registered in Maharashtra.
Synergypharma Formulations (India) operated in the pharma industry, in the drug formulation and development segment. It worked in this industry before it was struck off.
The peers of Synergypharma Formulations (India) by revenue are Vivimed Labs (Alathur) Private Limited, Neptune Lifesciences Pvt Ltd, Suncare Formulations Private Limited, Prim Drugs & Pharmaceuticals (India) Private Limited, Challa Chlorides Pvt Ltd, all in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Subramanian Ramaswamy Vaidya ceased to be Director on 21 Oct 2023. Shalini Nair ceased to be Additional Director on 30 Sep 2021. Shalini Nair was appointed as Director on 18 Feb 2020. Synergypharma Formulations (India) has 5 board changes on record in total.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
